G6PD and non-autoimmune hemolytic anemia: Although this study was unable to confirm the efficacy previously demonstrated in larger studies, close monitoring of study participants confirmed the safety and tolerability of SLD primaquine in the local study population, including in 17 patients who carried the G6PD A− variant associated with an increased risk of haemolytic anaemia when exposed to 8-aminoquinolines.